

Table 1. Demographic Data of the Patients and Data Related to the Surgery.

Characteristic	Ciprofol (N=99)	Propofol (N=105)
Age (yr), mean(SD)	51.58(9.88)	49.58(10.72)
Female sex, <i>n</i> /total <i>N</i> (%)	49/99(49.5%)	46/105(43.8%)
Height (cm), mean (SD)	166.09(8.08)	167.26(7.95)
Weight (kg), mean (SD)	67.41(12.07)	66.75(11.32)
BMI (kg·m ⁻²), mean (SD)	24.31(3.13)	23.77(2.97)
ASA Physical Status, <i>n</i> /total <i>N</i> (%)		
Grade II	83/99(83.8%)	84/105(80.0%)
Grade III	16/99(16.2%)	21/105(20.0%)
MOAA/S	5.0	5.0
ALT (U/L), mean (SD)	58.57(48.85)	50.94(57.02)
AST (U/L), mean (SD)	33.52(22.44)	27.37(15.28)
Cr (μmol/L), mean (SD)	75.31(29.13)	72.56(25.23)
Smoking Status, <i>n</i> /total <i>N</i> (%)		
Never	70/99(70.7%)	73/105(69.5%)
Current	23/99 (23.2%)	27/105(25.7%)
Past	6/99(6.1%)	5/105(4.8%)
Drinking Status, <i>n</i> /total <i>N</i> (%)		
Never	60/99(60.6%)	58/105(55.2%)
Current	29/99(29.3%)	33/105(31.4%)
Past	10/99(10.1%)	14/105(13.4%)
Chronic disease, <i>n</i> /total <i>N</i> (%)	32/99(32.3%)	40/105(38.1%)
Liquid intake(ml), mean (SD)	491.25(27.54)	493.3(28.10)
Duration of surgery(min), mean (SD)	60.5(4.47)	62.81(5.78)

ASA: American Society of Anesthesiologists; BMI: body mass index; SD: standard deviation; MOAA/S: Modified Observer's Assessment of Alertness/Sedation Scale score.

Table 2. Comparison of TTE Parameters

<i>outcomes</i>	Ciprofol (n=99)		<i>P</i> -value	Propofol (n=105)		<i>P</i> -value
	T ₀	T ₁		T ₀	T ₁	
TAPSE	2.61±0.36	2.42±0.37	< 0.001	2.70±0.40	2.38±0.35	< 0.001
Ea	9.41±2.54	8.70±2.11	0.039	9.24±2.03	8.65±1.92	0.037
Sa	8.83±1.65	8.73±1.37	0.607	8.53±1.24	8.21±1.10 ^a	0.004

^a*p*=0.004, C group T₁ VS P group T₁.

Table 3. Comparison of Heart Rate and Blood Pressure Parameters

<i>outcomes</i>	Ciprofol (n=99)		<i>P</i> -value	Propofol (n=105)		<i>P</i> -value
	T ₀	T ₁		T ₀	T ₁	
SBP	136.92±18.87	105.44±16.45	< 0.001	140.94±19.45	100.26±14.10 ^a	< 0.001
DBP	79.22±11.73	62.08±10.60	< 0.001	80.49±13.70	59.83±10.27	< 0.001
MAP	98.14±16.52	77.39±12.82	< 0.001	101.87±15.10	74.86±11.89	< 0.001
HR	76.61±12.90	70.81±11.65	< 0.001	77.97±12.22	71.49±10.72 ^b	< 0.001

^a*p*=0.016, C group T₁ VS P group T₁; ^b*p*=0.666, C group T₁ VS P group T₁.

Table 4. Comparison of Vasoactive Drug Use and Perioperative Adverse Events, n(%)

<i>Secondary outcomes</i>	Ciprofol (n=99)	Propofol (n=105)	<i>P</i> -value
ephedrine, <i>n</i> /total <i>N</i> (%)	22/99(22.2%)	35/105(33.0%)	0.09
phenylephrine, <i>n</i> /total <i>N</i> (%)	26/99(26.3%)	32/105(30.5%)	0.54
atropine, <i>n</i> /total <i>N</i> (%)	10/99(11.0%)	13/105(12.4%)	0.66
coughing, <i>n</i> /total <i>N</i> (%)	17/99(17.2%)	13/105(12.4%)	0.43
intraoperative movements, <i>n</i> /total <i>N</i> (%)	14/99(14%)	16/105(16%)	0.85
bradycardia, <i>n</i> /total <i>N</i> (%)	18/99(18.2%)	15/105(14.3%)	0.57
Injection-related pain, <i>n</i> /total <i>N</i> (%)	4/99(4.0%)	61/105(59%)	0.00
Respiratory depression, <i>n</i> /total <i>N</i> (%)	10/99(10.1%)	41/105(39%)	0.00
Intraoperative awareness, <i>n</i> /total <i>N</i> (%)	0/99(0%)	0/105(0%)	1.0
Agitation, <i>n</i> /total <i>N</i> (%)	4(4.0)	5/105(4.8%)	1.00
nausea or vomiting within 48 hours, <i>n</i> /total <i>N</i> (%)	8(9)	15/105(14%)	0.19

